Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 13/20 | 0.59 |
| ▸ | PSEN1 | P49768 | 6/20 | 0.53 |
| ▸ | PSEN2 | P49810 | 6/20 | 0.53 |
| ▸ | APH1B | Q8WW43 | 6/20 | 0.53 |
| ▸ | NCSTN | Q92542 | 6/20 | 0.53 |
| ▸ | APH1A | Q96BI3 | 6/20 | 0.53 |
| ▸ | PSENEN | Q9NZ42 | 6/20 | 0.53 |
| ▸ | CNR1 | P21554 | 1/20 | 0.53 |
| ▸ | PGR | P06401 | 1/20 | 0.50 |
| ▸ | RORA | P35398 | 1/20 | 0.50 |
| ▸ | RORC | P51449 | 1/20 | 0.50 |
| ▸ | RORB | Q92753 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27641643 | 1.00 | CNR2 (0.59) | CNR2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL1921229 | 0.94 | RORA (0.56) | CNR2CNR1PGRRORARORC | |
| SCHEMBL8143866 | 0.92 | PSEN1 (0.52) | CNR2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL4353679 | 0.92 | PSEN1 (0.52) | CNR2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL14893382 | 0.92 | PSEN1 (0.52) | CNR2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL4802610 | 0.92 | MAOA (0.53) | CNR2 | |
| SCHEMBL2957510 | 0.92 | PSEN1 (0.52) | CNR2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL4804298 | 0.92 | MAOA (0.53) | CNR2 | |
| SCHEMBL1921258 | 0.88 | HPGD (0.60) | CNR2CNR1PGRRORARORC | |
| SCHEMBL9905344 | 0.86 | PSEN1 (0.62) | CNR2PSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140301937-A1 | FULLERENE SEPARATION THROUGH USE OF ORGANIC CAGES | NATIONAL SCIENCE FOUNDATION | 2014-10-09 | — | — | US | disclosed |
| US-20140301937-A1 | FULLERENE SEPARATION THROUGH USE OF ORGANIC CAGES | NATIONAL SCIENCE FOUNDATION | 2014-10-09 | — | — | US | disclosed |
| WO-2013063368-A1 | FULLERENE SEPARATION THROUGH USE OF ORGANIC CAGES | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2013-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140301937-A1 | FULLERENE SEPARATION THROUGH USE OF ORGANIC CAGES | CYCS, NOP2, NCL | CNR2 2539/4885PSEN1 3196/4885PSEN2 1951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.